Home | Contact Us  
Tempero’s mission is to develop next-generation therapies that selectively suppress Th17-cells and enhance specialized Treg cells. We believe that therapies that modulate only select arms of the immune response are predicted to effectively treat autoimmune disorders such as multiple sclerosis, inflammatory bowel disease, psoriasis, type 1 diabetes and rheumatoid arthritis without broadly suppressing the immune system.

Tempero co-authors a paper in the March 15th, 2014 Journal of Immunology.  To view this article click here. 

Tempero's Thaddeus Carlson coauthors a paper in the Journal of Immunology on January 31. 2014 here and one in the Journal of Experimental Medicine on January 6. 2014 here.


  © 2009 Tempero Pharmaceuticals. All Rights Reserved.